Marta Guasch-Ferré1, Yan Zheng2, Miguel Ruiz-Canela3, Adela Hruby2, Miguel A Martínez-González3, Clary B Clish4, Dolores Corella5, Ramon Estruch6, Emilio Ros7, Montserrat Fitó8, Courtney Dennis4, Isabel M Morales-Gil9, Fernando Arós10, Miquel Fiol11, José Lapetra12, Lluís Serra-Majem13, Frank B Hu14, Jordi Salas-Salvadó15. 1. Departments of Nutrition and Human Nutrition Department, Pere Virgili Research Institute, University Hospital of Sant Joan de Reus, Rovira i Virgili University, Reus, Spain; The Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition, Health Institute Carlos III, Madrid, Spain; 2. Departments of Nutrition and. 3. The Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition, Health Institute Carlos III, Madrid, Spain; Department of Preventive Medicine and Public Health, University of Navarra-Medical Research Institute of Navarra, Pamplona, Spain; 4. Broad Institute of MIT and Harvard University, Cambridge, MA; 5. The Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition, Health Institute Carlos III, Madrid, Spain; Department of Preventive Medicine, University of Valencia, Valencia, Spain; 6. The Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition, Health Institute Carlos III, Madrid, Spain; Department of Internal Medicine and. 7. The Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition, Health Institute Carlos III, Madrid, Spain; Lipid Clinic, Department of Endocrinology and Nutrition, Biomedical Research Institute Agustí Pi Sunyer, Clinic Hospital, University of Barcelona, Barcelona, Spain; 8. The Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition, Health Institute Carlos III, Madrid, Spain; Cardiovascular and Nutrition Research Group, Hospital del Mar Research Institute, Barcelona, Spain; 9. Department of Infirmary, Faculty of Health Science, University of Malaga, Malaga, Spain; 10. Department of Cardiology, University Hospital of Alava, Vitoria, Spain; 11. Institute of Health Sciences of University of Balearic Islands and Hospital Son Espases, Palma de Mallorca, Spain; 12. The Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition, Health Institute Carlos III, Madrid, Spain; Department of Family Medicine, Primary Care Division of Sevilla, San Pablo Health Center, Sevilla, Spain; 13. The Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition, Health Institute Carlos III, Madrid, Spain; Department of Clinical Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain; and. 14. Departments of Nutrition and Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA; Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA. 15. Human Nutrition Department, Pere Virgili Research Institute, University Hospital of Sant Joan de Reus, Rovira i Virgili University, Reus, Spain; The Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition, Health Institute Carlos III, Madrid, Spain; jordi.salas@urv.cat.
Abstract
BACKGROUND: Previous studies have suggested that metabolite profiles of elevated acylcarnitines were associated with increased risk of cardiovascular disease (CVD) in populations with established coronary disease. However, to our knowledge, this association has not been evaluated in the context of primary cardiovascular prevention. OBJECTIVES: We evaluated the association between 28 plasma acylcarnitine species and risk of incident CVD and the potential modifying effect of Mediterranean diet (MedDiet) interventions. DESIGN: We measured plasma acylcarnitines with the use of high-throughput liquid chromatography-tandem mass spectrometry at baseline and after 1 y of follow-up, both individually and classified into short-, medium-, or long-chain scores, in a case-cohort study within the Prevención con Dieta Mediterránea (PREDIMED) study, which is a randomized Mediterranean dietary intervention for primary cardiovascular prevention. A randomly selected subcohort (n = 751) and all available incident CVD cases (n = 229) after 4.8 y of follow-up were included in the current study. RESULTS: After adjustment for age, sex, body mass index, and other CVD risk factors, participants in the highest quartile of baseline short- and medium-chain acylcarnitines had a higher risk of CVD than did participants in the lowest quartile [HRs: 1.80 (95% CI: 1.11, 2.91; P-trend 0.01) and 1.55 (95% CI: 1.01, 2.48; P-trend = 0.04), respectively]. Increased short-chain acylcarnitines after 1 y were associated with higher risks of total CVD and stroke. Participants with higher baseline concentrations of short-, medium-, and long-chain acylcarnitines who were randomly assigned to the control group had a higher risk of CVD than did subjects with lower concentrations of acylcarnitines who were assigned to the MedDiet group. CONCLUSIONS: Our data support the conclusion that metabolite profiles characterized by elevated concentrations of acylcarnitines are independently associated with risks of total CVD and stroke alone in participants at high risk of CVD. MedDiet interventions may mitigate the adverse associations shown between higher concentrations of acylcarnitines and CVD. This trial was registered at www.controlled-trials.com as ISRCTN35739639.
RCT Entities:
BACKGROUND: Previous studies have suggested that metabolite profiles of elevated acylcarnitines were associated with increased risk of cardiovascular disease (CVD) in populations with established coronary disease. However, to our knowledge, this association has not been evaluated in the context of primary cardiovascular prevention. OBJECTIVES: We evaluated the association between 28 plasma acylcarnitine species and risk of incident CVD and the potential modifying effect of Mediterranean diet (MedDiet) interventions. DESIGN: We measured plasma acylcarnitines with the use of high-throughput liquid chromatography-tandem mass spectrometry at baseline and after 1 y of follow-up, both individually and classified into short-, medium-, or long-chain scores, in a case-cohort study within the Prevención con Dieta Mediterránea (PREDIMED) study, which is a randomized Mediterranean dietary intervention for primary cardiovascular prevention. A randomly selected subcohort (n = 751) and all available incident CVD cases (n = 229) after 4.8 y of follow-up were included in the current study. RESULTS: After adjustment for age, sex, body mass index, and other CVD risk factors, participants in the highest quartile of baseline short- and medium-chain acylcarnitines had a higher risk of CVD than did participants in the lowest quartile [HRs: 1.80 (95% CI: 1.11, 2.91; P-trend 0.01) and 1.55 (95% CI: 1.01, 2.48; P-trend = 0.04), respectively]. Increased short-chain acylcarnitines after 1 y were associated with higher risks of total CVD and stroke. Participants with higher baseline concentrations of short-, medium-, and long-chain acylcarnitines who were randomly assigned to the control group had a higher risk of CVD than did subjects with lower concentrations of acylcarnitines who were assigned to the MedDiet group. CONCLUSIONS: Our data support the conclusion that metabolite profiles characterized by elevated concentrations of acylcarnitines are independently associated with risks of total CVD and stroke alone in participants at high risk of CVD. MedDiet interventions may mitigate the adverse associations shown between higher concentrations of acylcarnitines and CVD. This trial was registered at www.controlled-trials.com as ISRCTN35739639.
Authors: C Lawrence Kien; Karen I Everingham; Robert D Stevens; Naomi K Fukagawa; Deborah M Muoio Journal: Obesity (Silver Spring) Date: 2010-06-17 Impact factor: 5.002
Authors: Ramón Estruch; Emilio Ros; Jordi Salas-Salvadó; Maria-Isabel Covas; Dolores Corella; Fernando Arós; Enrique Gómez-Gracia; Valentina Ruiz-Gutiérrez; Miquel Fiol; José Lapetra; Rosa Maria Lamuela-Raventos; Lluís Serra-Majem; Xavier Pintó; Josep Basora; Miguel Angel Muñoz; José V Sorlí; José Alfredo Martínez; Miguel Angel Martínez-González Journal: N Engl J Med Date: 2013-02-25 Impact factor: 91.245
Authors: C Lawrence Kien; Janice Y Bunn; Robert Stevens; James Bain; Olga Ikayeva; Karen Crain; Timothy R Koves; Deborah M Muoio Journal: Am J Clin Nutr Date: 2014-01-15 Impact factor: 7.045
Authors: Sean H Adams; Charles L Hoppel; Kerry H Lok; Ling Zhao; Scott W Wong; Paul E Minkler; Daniel H Hwang; John W Newman; W Timothy Garvey Journal: J Nutr Date: 2009-04-15 Impact factor: 4.798
Authors: Julie A Schmidt; Sabina Rinaldi; Pietro Ferrari; Marion Carayol; David Achaintre; Augustin Scalbert; Amanda J Cross; Marc J Gunter; Georgina K Fensom; Paul N Appleby; Timothy J Key; Ruth C Travis Journal: Am J Clin Nutr Date: 2015-10-28 Impact factor: 7.045
Authors: Sahir Kalim; Clary B Clish; Julia Wenger; Sammy Elmariah; Robert W Yeh; Joseph J Deferio; Kerry Pierce; Amy Deik; Robert E Gerszten; Ravi Thadhani; Eugene P Rhee Journal: J Am Heart Assoc Date: 2013-12-05 Impact factor: 5.501
Authors: Ranee Chatterjee; Clemontina A Davenport; Lydia Kwee; David D'Alessio; Laura P Svetkey; Pao-Hwa Lin; Cris A Slentz; Olga Ilkayeva; Johanna Johnson; David Edelman; Svati H Shah Journal: Metabolomics Date: 2020-06-18 Impact factor: 4.290
Authors: Samantha Molsberry; Kjetil Bjornevik; Katherine C Hughes; Zhongli Joel Zhang; Sarah Jeanfavre; Clary Clish; Brian Healy; Michael Schwarzschild; Alberto Ascherio Journal: J Parkinsons Dis Date: 2020 Impact factor: 5.568
Authors: Marta Guasch-Ferré; Miguel Ruiz-Canela; Jun Li; Yan Zheng; Mònica Bulló; Dong D Wang; Estefanía Toledo; Clary Clish; Dolores Corella; Ramon Estruch; Emilio Ros; Montserrat Fitó; Fernando Arós; Miquel Fiol; José Lapetra; Lluís Serra-Majem; Liming Liang; Christopher Papandreou; Courtney Dennis; Miguel A Martínez-González; Frank B Hu; Jordi Salas-Salvadó Journal: J Clin Endocrinol Metab Date: 2019-05-01 Impact factor: 5.958
Authors: Yiwei Ma; Liang Sun; Jun Li; Yao Hu; Zhenji Gan; Geng Zong; He Zheng; Qianlu Jin; Huaixing Li; Frank B Hu; Rong Zeng; Qi Sun; Xu Lin Journal: J Lipid Res Date: 2018-12-14 Impact factor: 5.922
Authors: Mònica Bulló; Christopher Papandreou; Miguel Ruiz-Canela; Marta Guasch-Ferré; Jun Li; Pablo Hernández-Alonso; Estefania Toledo; Liming Liang; Cristina Razquin; Dolores Corella; Ramon Estruch; Emilio Ros; Montserrat Fitó; Fernando Arós; Miquel Fiol; Lluís Serra-Majem; Clary B Clish; Nerea Becerra-Tomás; Miguel A Martínez-González; Frank B Hu; Jordi Salas-Salvadó Journal: J Nutr Date: 2021-01-04 Impact factor: 4.798
Authors: Edward Yu; Miguel Ruiz-Canela; Marta Guasch-Ferré; Yan Zheng; Estefania Toledo; Clary B Clish; Jordi Salas-Salvadó; Liming Liang; Dong D Wang; Dolores Corella; Montse Fitó; Enrique Gómez-Gracia; José Lapetra; Ramón Estruch; Emilio Ros; Montserrat Cofán; Fernando Arós; Dora Romaguera; Lluis Serra-Majem; Jose V Sorlí; Frank B Hu; Miguel A Martinez-Gonzalez Journal: J Nutr Date: 2017-02-08 Impact factor: 4.798